{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Orlando&page=6&state=Florida", "query": { "state": "Florida", "city": "Orlando", "page": 6 }, "page_size": 10 }, "pagination": { "page": 6, "page_size": 10, "total_count": 6841, "total_pages": 685, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Orlando&page=7&state=Florida&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Orlando&page=5&state=Florida&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-27T23:40:35.912Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03897881", "title": "An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "mRNA-4157", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "ModernaTX, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 267, "start_date": "2019-07-18", "completion_date": "2032-11-21", "has_results": false, "last_update_posted_date": "2026-09-08", "last_synced_at": "2026-10-27T23:40:35.912Z", "location_count": 17, "location_summary": "Tucson, Arizona • San Francisco, California • Santa Monica, California + 13 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT03897881" }, { "nct_id": "NCT06918730", "title": "U-POEM vs CO2-POEM", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Esophageal Motility Disorders" ], "interventions": [ { "name": "U-POEM", "type": "PROCEDURE" }, { "name": "CO2-POEM", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "AdventHealth", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2025-02-11", "completion_date": "2026-03-03", "has_results": false, "last_update_posted_date": "2026-05-15", "last_synced_at": "2026-10-27T23:40:35.912Z", "location_count": 1, "location_summary": "Orlando, Florida", "locations": [ { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06918730" }, { "nct_id": "NCT05840211", "title": "Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Locally Advanced or Unresectable Metastatic Breast Cancer", "Stage IV Breast Cancer" ], "interventions": [ { "name": "Sacituzumab Govitecan-hziy", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 654, "start_date": "2023-05-08", "completion_date": "2028-04", "has_results": false, "last_update_posted_date": "2025-10-03", "last_synced_at": "2026-10-27T23:40:35.912Z", "location_count": 30, "location_summary": "Chandler, Arizona • Los Angeles, California • Palo Alto, California + 25 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Littleton", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05840211" }, { "nct_id": "NCT01554696", "title": "A Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects Who Have Had an Inadequate Response to Methotrexate", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Arthritis, Rheumatoid" ], "interventions": [ { "name": "peficitinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 379, "start_date": "2012-07-06", "completion_date": "2014-02-11", "has_results": false, "last_update_posted_date": "2025-05-29", "last_synced_at": "2026-10-27T23:40:35.912Z", "location_count": 19, "location_summary": "Birmingham, Alabama • Huntington Beach, California • La Jolla, California + 16 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntington Beach", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Palm Desert", "state": "California" }, { "city": "Santa Maria", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01554696" }, { "nct_id": "NCT01436162", "title": "Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Major Depressive Disorder" ], "interventions": [ { "name": "Antidepressant + SPD489 (Lisdexamfetamine dimesylate )", "type": "DRUG" }, { "name": "Antidepressant + Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shire", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 1105, "start_date": "2011-10-19", "completion_date": "2013-12-10", "has_results": true, "last_update_posted_date": "2021-06-09", "last_synced_at": "2026-10-27T23:40:35.912Z", "location_count": 36, "location_summary": "Scottsdale, Arizona • Little Rock, Arkansas • Costa Mesa, California + 31 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Costa Mesa", "state": "California" }, { "city": "Downey", "state": "California" }, { "city": "Escondido", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01436162" }, { "nct_id": "NCT04323761", "title": "Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)", "overall_status": "APPROVED_FOR_MARKETING", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "SARS-CoV2 Infection" ], "interventions": [ { "name": "Remdesivir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2020-11-13", "last_synced_at": "2026-10-27T23:40:35.912Z", "location_count": 165, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 130 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Fresno", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04323761" }, { "nct_id": "NCT03924856", "title": "Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Bladder Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND])", "type": "PROCEDURE" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 907, "start_date": "2019-06-13", "completion_date": "2026-05-18", "has_results": false, "last_update_posted_date": "2026-10-08", "last_synced_at": "2026-10-27T23:40:35.912Z", "location_count": 24, "location_summary": "La Jolla, California • Santa Monica, California • Washington D.C., District of Columbia + 21 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Orlando", "state": "Florida" }, { "city": "Fort Wayne", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT03924856" }, { "nct_id": "NCT06533553", "title": "A Study to Assess the Effects of Dexpramipexole in Participants With Eosinophilic COPD", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Obstructive Pulmonary Disease" ], "interventions": [ { "name": "Dexpramipexole Dihydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Areteia Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "40 Years to 80 Years" }, "enrollment_count": 30, "start_date": "2024-07-09", "completion_date": "2025-12", "has_results": false, "last_update_posted_date": "2025-05-14", "last_synced_at": "2026-10-27T23:40:35.912Z", "location_count": 23, "location_summary": "Conway, Arkansas • Newport Beach, California • Northridge, California + 19 more", "locations": [ { "city": "Conway", "state": "Arkansas" }, { "city": "Newport Beach", "state": "California" }, { "city": "Northridge", "state": "California" }, { "city": "Westminster", "state": "California" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06533553" }, { "nct_id": "NCT01699737", "title": "Safety and Efficacy Study of JTT-851 in Patients With Type 2 Diabetes Mellitus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "JTT-851", "type": "DRUG" }, { "name": "Glimepiride", "type": "DRUG" }, { "name": "Placebo for Active", "type": "DRUG" }, { "name": "Placebo for comparator", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Akros Pharma Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 325, "start_date": "2012-09", "completion_date": "2013-07", "has_results": false, "last_update_posted_date": "2013-08-01", "last_synced_at": "2026-10-27T23:40:35.912Z", "location_count": 79, "location_summary": "Birmingham, Alabama • Dothan, Alabama • Huntsville, Alabama + 76 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Dothan", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Montgomery", "state": "Alabama" }, { "city": "Muscle Shoals", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT01699737" }, { "nct_id": "NCT02032277", "title": "A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Triple Negative Breast Cancer" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Veliparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "FEMALE", "summary": "18 Years to 99 Years · Female only" }, "enrollment_count": 634, "start_date": "2014-04-02", "completion_date": "2020-11-12", "has_results": false, "last_update_posted_date": "2021-01-20", "last_synced_at": "2026-10-27T23:40:35.912Z", "location_count": 61, "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 47 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Salinas", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02032277" } ] }